ArticleEndocrinology2026
Ethinyl estradiol and levonorgestrel coadministration induces hypophagia and increases energy expenditure in female rats.
Article in Endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Region-specific regulation of glucocorticoid and mineralocorticoid receptor signaling in a mouse model of oral contraceptive exposure.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Oral contraceptives containing ethinyl estradiol (EE) with levonorgestrel (LNG) are common in hormonal contraceptives. EE+LNG suppresses weight gain in rodents, but the mechanisms for this remain unclear. Further, metabolic demands in adolescence are increased relative to adulthood. We tested the metabolic effect of a low dose of EE + LNG in adolescents and adult female Long-Evans rats. Rats were given EE (10 µg/kg) + LNG (20 µg/kg) or vehicle subcutaneous injections daily for 16 days. Body mass, food intake, whole-body oxygen consumption, respiratory exchange ratio, and energy expenditure were measured in Promethion phenotyping cages. Dual-energy X-ray absorptiometry (DXA), glucose tolerance, serum metabolic hormone levels, depot-specific adipose and reproductive tissues were collected. EE+LNG limited body-mass gain in both age groups by combining hypophagia with a marked elevation in total energy expenditure and no change in locomotion, implicating potential thermogenic pathways. Dual-energy X-ray absorptiometry scans showed curtailed fat accrual and the preservation of lean mass in EE + LNG-treated rats. White-adipose depots were smaller in all hormone-treated rats, whereas brown adipose tissue mass was reduced only in adults. EE+LNG-treated adults had lower leptin and C-peptide levels with enhanced glucose clearance, whereas adolescents had reductions in GLP-1, glucagon, and PYY levels without altered glucose clearance. Thus low-dose EE + LNG reduced caloric intake, increased energy expenditure, and limited white-adipose deposition irrespective of age. Age-specific effects on metabolic hormones and adipose depot UCP1 content were noted. Together, these results delineate an age-sensitive metabolic and endocrine profile of EE + LNG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.